Dupilumab Ups Histologic Response for Pediatric Eosinophilic Esophagitis
By Elana Gotkine HealthDay Reporter
THURSDAY, June 27, 2024 -- For children with eosinophilic esophagitis, dupilumab results in a significantly higher percentage of histologic remission, according to a study published in the June 27 issue of the New England Journal of Medicine.
Mirna Chehade, M.D., M.P.H., from Icahn School of Medicine at Mount Sinai in New York City, and colleagues randomly assigned patients aged 1 to 11 years of age with active eosinophilic esophagitis who had had no response to proton-pump inhibitors to 16 weeks of a higher- or lower-exposure subcutaneous dupilumab regimen or placebo (two groups) in a 2:2:1:1 ratio (Part A). At the end of Part A, in each dupilumab group, eligible patients continued the same regimen, while those in the placebo groups were assigned to 36 weeks of higher- or lower-exposure dupilumab. Dupilumab was administered in one of four doses tiered according to baseline body weight at each level of exposure.
The researchers found that 68 percent of 37 patients in the higher-exposure group, 58 percent of the 31 patients in the lower-exposure group, and 3 percent of the 34 patients in the placebo group had histologic remission in Part A. Compared with placebo, significant improvements were seen in histologic, endoscopic, and transcriptomic measures in the higher-exposure dupilumab regimen. Between baseline and week 52, the improvements in histologic, endoscopic, and transcriptomic measures in all patients were generally similar to those between baseline and week 16 in the patients who received dupilumab in Part A.
"The higher-exposure regimen showed significant benefits as compared with placebo with respect to seven of the eight secondary end points," the authors write.
The study was funded by Sanofi and Regeneron Pharmaceuticals, which manufacture dupilumab.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Histologic Response Up With Benralizumab for Eosinophilic Esophagitis
WEDNESDAY, June 26, 2024 -- Benralizumab yields a greater histologic response than placebo for patients with eosinophilic esophagitis, but does not affect dysphagia symptoms...
FDA Approves Eohilia for Eosinophilic Esophagitis
FRIDAY, Feb. 16, 2024 -- The U.S. Food and Drug Administration has approved Eohilia (budesonide oral suspension) as the first and only oral treatment for eosinophilic esophagitis...
FDA Approves Dupilumab for Children With Eosinophilic Esophagitis
MONDAY, Jan. 29, 2024 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of pediatric patients (aged 1 to 11 years) with eosinophilic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.